Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effects of Selexipag on Cardiac Repolarization in Healthy Subjects
NCT02206204Phase 1Completed
- Sponsor
- Actelion Pharmaceuticals Ltd
- Start
- Jun 2012
- Primary completion
- Nov 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of selexipag in pulmonary arterial hypertension (PAH) (3 arms), sponsored by Actelion Pharmaceuticals Ltd. Primary endpoint: Baseline adjusted placebo corrected change in corrected QTc interval at 24 days. Started Jun 2012; status: completed.
02
Drugs
selexipag
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on NCT02206204.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02206204.